Jazz Pharmaceuticals lung cancer drug fails main trial goal

Jazz Pharmaceuticals said Zepzelca failed to meet the main endpoint of improving overall survival in a late-stage lung cancer study. The miss could jeopardize the drug's current regulatory status, creating a meaningful downside risk for the stock. The update is company-specific but significant enough to potentially move shares.

Analysis

Jazz Pharmaceuticals said Zepzelca failed to meet the main endpoint of improving overall survival in a late-stage lung cancer study. The miss could jeopardize the drug's current regulatory status, creating a meaningful downside risk for the stock. The update is company-specific but significant enough to potentially move shares.